On August 31, 2026, Reuters reported on a new study finding that patients who stay on the lowest starter doses of GLP-1 ...

Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S.

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

GLP-1 therapies are improving weight-loss outcomes, but research shows long-term success depends on adherence, muscle preservation, personalised guidance and continuous support beyond the prescription ...

European pharmaceutical giant Novo Nordisk (NVO) is rebranding as it pushes for market share in the increasingly competitive ...

In an early human trial, Eli Lilly's eloralintide helped people lose up to 20% of their body weight. Reading time 3 minutes The race to develop the next generation of weight loss drugs has taken an ...

Novo Nordisk's semaglutide, the active ingredient in Wegovy, mimics the action of the GLP-1 hormones, which play a role in regulating insulin and satiety. Wegovy is effective enough, but the company's ...

Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player. Is there any hope left for the ...

Just one day after two closely watched studies failed to show that Novo Nordisk's oral GLP-1 semaglutide slows the progression of Alzheimer's disease, the company reported encouraging phase 2 results ...

Novo Nordisk's clinical setback elevates Viking's VK2735 in obesity drug race. Viking holds $706M cash, plans Phase 3 oral trial for 2026 after stock surges 11%. A recent shift in the competitive ...

The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk plans to launch the once-daily oral semaglutide in the US in early January ...